We are international
Donate
TEXT SIZE   
back

Understanding Serum Free Light Chain and Serum Heavy/Light Chain Assays

This booklet is devoted to two tests used in the diagnosis and monitoring of myeloma, the serum free light chain assay (Freelite®) and the serum heavy/light chain assay (Hevylite®). Since Freelite and Hevylite are independent biomark­ers of disease activity, it is important to monitor patients with both tests. 

07.29.14

You can view the entire document as a PDF by clicking on the icon below.

Click Icon to View PDF

The Understanding Serum Free Light Chain and Serum Heavy/Light Chain Assays booklet is devoted to two tests used in the diagnosis and monitoring of myeloma, the serum free light chain assay (Freelite®) and the serum heavy/light chain assay (Hevylite®). 

Changes in Freelite levels are useful for tracking the disease status in almost all people with myeloma, not just those with light chain (Bence Jones) myeloma or nonsecretory disease. The Freelite test can help in the detection and monitoring of myeloma by quan­tifying monoclonal protein in multiple disease settings. While the Freelite test quantifies free light chains, the Hevylite test quantifies the intact (or whole) heavy and light chain pairsinvolved in a patient's myeloma. 

Myeloma cells from a single patient can produce multiple clones that may produce intact immunoglobulins, free light chains, or both. Since Freelite and Hevylite are independent biomark­ers of disease activity, it is important to monitor patients with both tests. Given the heterogeneity of clones in an individual patient’s myeloma, these two assays, when used together, are complementary.


 related videos
 related articles
ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
"Understanding Health Disparities in Cancer: The Case of Multiple Myeloma"
Understanding Adherence to Oral Cancer Therapy
ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
Best of ASH 2013: What Patients Need to Know
BLACK SWAN RESEARCH INITIATIVE™ DONOR LEVELS
BLACK SWAN RESEARCH INITIATIVE™ MEDIA CONTACT
BRAZIL WORKSHOP
California Support Group Leader’s Testimony Makes Huge Difference
Cancer Awareness Bracelets
IMF Nurse Leadership Board (NLB) Survivorship Care Plan for Mutliple Myeloma published in the Clinical Journal of Oncology Nursing.
International Myeloma Foundation (IMF)
Flow Workshop Presentations
July 18-19, 2014
International Myeloma Foundation Mission Statement
Mensajero del Mieloma - Otoño 2012 - #903
Michael and Robin Tuohy of Connecticut Help to Pass State Oral Parity Bill
Pomalidomide News: Promising Results Increase Chances of Early Drug Approval
Raise Your Voice Web Series
Sign up TODAY for Advocacy Training Two-Part Online Series!
Supreme Court Upholds Affordable Care Act
The International Myeloma Foundation Applauds Wisconsin Gov. Scott Walker for Signing SB 300 (The Cancer Treatment Fairness Act) into Law